USA flag logo/image

An Official Website of the United States Government

Biofilm development and Eye Infections

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
75648
Program Year/Program:
2005 / SBIR
Agency Tracking Number:
EY016293
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMULET PHARMACEUTICALS, INC.
AMULET PHARMACEUTICALS, INC. 9430 Key West Avenue Rockville, MD 20850
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2005
Title: Biofilm development and Eye Infections
Agency: HHS
Contract: 1R43EY016293-01
Award Amount: $117,240.00
 

Abstract:

Contact lens related eye infections impact millions of people yearly. Standard guidelines for lens care can minimize eye infection, but it has been shown that only about 50% of lens wearers adhere to appropriate guidelines. During usual use and storage procedures, microorganisms adhere to contact lenses. Daily lens cleaning removes most of these microorganisms, but sometimes microbes establish biofilms on lenses and often such biofilms are not satisfactorily removed despite disinfection and cleaning with systems currently available. In many cases the source of the microorganisms is the lens case where biofilms have developed. In addition to resistance to lens disinfectant/cleaning systems, biofilms formed by pathogenic organisms are of increasing clinical importance due to their resistance to antibiotics and host immune responses as well as their ability to develop on indwelling medical devices. Nitric oxide (NO) has been shown to efficiently kill bacteria and fungi in the mammalian host by the action of granulocytes that produce NO. We have previously exploited the antimicrobial properties of NO to create slow NO releasing compounds that are capable of killing both fungi and bacteria growing planktonically. In the present investigation, we will test the principle that such compounds are also capable of killing organisms growing in established biofilms. In this context, the aim of this Phase I proposal is to test the hypothesis that NO treatment is capable of killing microbial cells that comprise biofilms formed by causative agents of contact lens related eye infection. The sensitivity of appropriate bacterial, fungal, and mixed species biofilms to NO treatment will be determined. If proof of principle is obtained, the ultimate goal of the investigation to be pursued in Phase II is the development of an appropriate delivery vehicle for lens and lens case sterilization. We will initiate this work during Phase I, and possible approaches are also discussed herein.

Principal Investigator:

Robert E. Raulli
4104555747
RRAULLI@AOL.COM

Business Contact:


4104555747
Small Business Information at Submission:

Amulet Pharmaceuticals, Inc.
Amulet Pharmaceuticals, Inc. 1450 S Rolling Rd Halethorpe, MD 21227

EIN/Tax ID: 522334293
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No